Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS 3	APR 02	PATDPAFULL: Application and priority number formats enhanced
NEWS 4	APR 02	DWPI: New display format ALLSTR available
NEWS 5	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS 6	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS 7	APR 07	CA/CAplus CLASS Display Streamlined with Removal of Pre-IPC 8 Data Fields
NEWS 8	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in CAplus
NEWS 9	APR 07	MEDLINE Coverage Is Extended Back to 1947
NEWS 10	JUN 16	WPI First View (File WPIFV) will no longer be available after July 30, 2010
NEWS 11	JUN 18	DWPI: New coverage - French Granted Patents
NEWS 12	JUN 18	CAS and FIZ Karlsruhe announce plans for a new STN platform
NEWS 13	JUN 18	IPC codes have been added to the INSPEC backfile (1969-2009)
NEWS 14	JUN 21	Removal of Pre-IPC 8 data fields streamline displays in CA/CAplus, CASREACT,and MARPAT
NEWS 15	JUN 21	Access an additional 1.8 million records exclusively enhanced with 1.9 million CAS Registry Numbers -- EMBASE Classic on STN
NEWS 16	JUN 28	Introducing "CAS Chemistry Research Report": 40 Years of Biofuel Research Reveal China Now Atop U.S. in Patenting and Commercialization of Bioethanol
NEWS 17	JUN 29	Enhanced Batch Search Options in DGENE, USGENE, and PCTGEN
NEWS 18	JUL 19	Enhancement of citation information in INPADOC databases provides new, more efficient competitor analyses
NEWS 19	JUL 26	CAS coverage of global patent authorities has expanded to 61 with the addition of Costa Rica
NEWS 20	SEP 15	MEDLINE Cited References provide additional revelant records with no additional searching.

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2, AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

```
Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:24:45 ON 30 SEP 2010

=> fil reg
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.22       0.22

FILE 'REGISTRY' ENTERED AT 13:24:56 ON 30 SEP 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 SEP 2010  HIGHEST RN 1243818-26-9
DICTIONARY FILE UPDATES:  29 SEP 2010  HIGHEST RN 1243818-26-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s dmxaa
L1            3 DMXAA

=> d l1 1-3

L1   ANSWER 1 OF 3  REGISTRY  COPYRIGHT 2010 ACS on STN
RN   853799-58-3  REGISTRY
ED   Entered STN:  05 Jul 2005
CN   9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo-, mixt. with
     2-[(2,6-dichlorophenyl)amino]benzeneacetic acid (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   DMXAA-diclofenac mixture
MF   C17 H14 O4 . C14 H11 Cl2 N O2
CI   MXS
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

     CM   1
```

CRN 117570-53-3
CMF C17 H14 O4



CM 2

CRN 15307-86-5
CMF C14 H11 Cl2 N O2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2010 ACS on STN
RN 129095-08-5 REGISTRY
ED Entered STN: 31 Aug 1990
CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo-, sodium salt (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo-, sodium salt (9CI)
OTHER NAMES:
CN DMXAA sodium salt
MF C17 H14 O4 . Na
CI COM
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, IMSPATENTS, IMSRESEARCH, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (117570-53-3)



7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2010 ACS on STN
RN 117570-53-3 REGISTRY
ED Entered STN: 18 Nov 1988
CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)
OTHER NAMES:
CN 5,6-Dimethyl-9-oxo-9H-xanthen-4-ylacetic acid
CN 5,6-Dimethylxanthenone-4-acetic acid
CN AS 1404
CN ASA 404
CN DMXAA
CN NSC 640488
CN Vadimezan
MF C17 H14 O4
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CIN, EMBASE, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, PROMT, PROUSDDR, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

212 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
215 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	12.29	12.51

FILE 'CAPLUS' ENTERED AT 13:25:13 ON 30 SEP 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Sep 2010 VOL 153 ISS 14
FILE LAST UPDATED: 29 Sep 2010 (20100929/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2010

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l1
L2 216 L1

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.50	13.01

FILE 'REGISTRY' ENTERED AT 13:25:20 ON 30 SEP 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 29 SEP 2010 HIGHEST RN 1243818-26-9
DICTIONARY FILE UPDATES: 29 SEP 2010 HIGHEST RN 1243818-26-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> s gemcitabine
L3          15 GEMCITABINE

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     5.99      19.00

FILE 'CAPLUS' ENTERED AT 13:25:29 ON 30 SEP 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 30 Sep 2010  VOL 153 ISS 14
FILE LAST UPDATED: 29 Sep 2010  (20100929/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Aug 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Aug 2010

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4        6347 L3

=> d his

     (FILE 'HOME' ENTERED AT 13:24:45 ON 30 SEP 2010)

     FILE 'REGISTRY' ENTERED AT 13:24:56 ON 30 SEP 2010
L1             3 S DMXAA

     FILE 'CAPLUS' ENTERED AT 13:25:13 ON 30 SEP 2010
L2           216 S L1

     FILE 'REGISTRY' ENTERED AT 13:25:20 ON 30 SEP 2010
L3            15 S GEMCITABINE

     FILE 'CAPLUS' ENTERED AT 13:25:29 ON 30 SEP 2010
L4          6347 S L3

=> s l2 and l4
```

```
L5            9 L2 AND L4

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6            9 DUP REM L5 (0 DUPLICATES REMOVED)

=> d l6 1-9 ibib abs

L6   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2010:1127861  CAPLUS
TITLE:                    Surface topographies for non-toxic bioadhesion control
INVENTOR(S):              Brennan, Anthony B.; Long, Christopher James; Bagan,
                          Joseph W.; Schumacher, James Frederick; Spiecker, Mark
                          M.
PATENT ASSIGNEE(S):       University of Florida, USA
SOURCE:                   U.S. Pat. Appl. Publ., 64pp., Cont.-in-part of U.S.
                          Ser. No. 567,103.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   3
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
     US 20100226943       A1    20100909    US 2009-550870         20090831
     US 20050178286       A1    20050818    US 2004-780424         20040217
     US 7650848           B2    20100126    US 2006-567103         20061205
PRIORITY APPLN. INFO.:                      US 2004-780424      A2 20040217
                                            US 2005-202532      A2 20050812
                                            US 2006-567103      A2 20061205
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB   The invention relates to articles and related devices and systems having
     surface topog. and/or surface elastic properties for providing non-toxic
     bioadhesion control.  An article includes a first plurality of spaced
     features arranged in a plurality of groupings including repeat units.  The
     spaced features within a grouping are spaced apart at an average distance of
     about 1 nm to about 500 μm, each feature having a surface that is
     substantially parallel to a surface on a neighboring feature separated from
     its neighboring feature.  The groupings of features are arranged with
     respect to one another so as to define a tortuous pathway.  The plurality
     of spaced features provide the article with an engineered roughness index
     of about 5 to about 20.

L6   ANSWER 2 OF 9  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2009:1536640  CAPLUS
DOCUMENT NUMBER:          152:37275
TITLE:                    Preparation of dihydro-iso-CA-4 and analogues as
                          potent cytotoxic compounds and inhibitors of tubulin
                          polymerization
INVENTOR(S):              Alami, Mouad; Messaoudi, Samir; Hamze, Abdallah;
                          Provot, Olivier; Brion, Jean-Daniel; Liu, Jian-Miao;
                          Bignon, Jerome; Bakala, Joanna
PATENT ASSIGNEE(S):       Centre National de la Recherche Scientifique (CNRS),
                          Fr.
SOURCE:                   PCT Int. Appl., 106pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 French
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009147217	A1	20091210	WO 2009-EP56885	20090604
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
FR 2932180	A1	20091211	FR 2008-53694	20080604
PRIORITY APPLN. INFO.:			FR 2008-53694 A	20080604
OTHER SOURCE(S):	MARPAT 152:37275			

GI



AB Dihydro-iso-CA-4 analogs I [R1, R3 = MeO substituted with fluorine; R2, R4 = H, MeO substituted with fluorine; Z = aryl, heteroaryl; X = N, CH; Z1 = H, F; Z2 = H, F, (C1–C4) alkyl, CN, SO3R9, CO2R15, COR15; R9 = (C1–C4) alkyl, aryl, heteroaryl; R15 = H, (C1–C4) alkyl, aryl, heteroaryl, (CH2)mCO2H, (CH2)mNR7R8, m = 1–3; R7, R8 = H, (C1–C4) alkyl, aryl, heteroaryl] were prepared as antitumor agents and tubulin polymerization inhibitors. For example, reacting (trimethoxyphenyl)(hydroxymethoxyphenyl)ethene II (R = H, Y = CH2) with ClCONEt2 gave II (R = CONEt2, Y = CH2) which was hydrogenated to give II (R = CONEt2, Y = H,H). Several compds. were tested for cytotoxic activity against colorectal carcinoma, lung cancer and leukemia. The compds. are also useful as tubulin polymerization inhibitors and antivascular compds.

OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	10	THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER:	2009:739059 CAPLUS
DOCUMENT NUMBER:	151:86657
TITLE:	Combinations of therapeutic agents comprising vascular disrupting agent such as 5,6-dimethylxanthenone-4-acetic acid, for treating cancer
INVENTOR(S):	Evans, Dean Brent; Jacques, Christian J.
PATENT ASSIGNEE(S):	Novartis A.-G., Switz.
SOURCE:	PCT Int. Appl., 57pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009076170	A2	20090618	WO 2008-US85535	20081204
WO 2009076170	A3	20090730		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2008335469	A1	20090618	AU 2008-335469	20081204
CA 2708149	A1	20090618	CA 2008-2708149	20081204
KR 2010103819	A	20100928	KR 2010-7015354	20081204
EP 2231147	A2	20100929	EP 2008-860391	20081204

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS

PRIORITY APPLN. INFO.:	US 2007-13335P	P	20071213
	WO 2008-US85535	W	20081204

AB The invention relates to a combination comprising vascular disrupting agent (VDA), such as 5,6-dimethylxanthenone-4-acetic acid or a pharmaceutically acceptable salt, ester or prodrug thereof; and one or more pharmaceutically active agents; pharmaceutical compns. comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a com. package comprising said combination. Thus, the effects of 5,6-dimethylxanthenone-4-acetic acid (Compound A), trastuzumab and paclitaxel are evaluated for their antitumor activity using the BT-474 human breast ductal carcinoma xenograft model; the data shows that Compound A at 20 mg/kg given i.v. on days 1, 5 and 9 is able to produce inhibition of tumor growth; paclitaxel combined with trastuzumab is also active resulting in a combination effect; when Compound A at 20 mg/kg is combined with paclitaxel and trastuzumab, increased activity is apparent resulting in tumor regressions; using the Clark Combination Index method, synergy is indicated; the tolerability of the triple combinations is no worse than that observed when Compound A is dosed alone.

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER:	2009:1543075 CAPLUS
DOCUMENT NUMBER:	152:57082
TITLE:	Preparation of dihydro-iso-CA-4 and analogues as potent cytotoxic compounds and inhibitors of tubulin polymerization
INVENTOR(S):	Alami, Mouad; Messaoudi, Samir; Hamze, Abdallah; Provot, Olivier; Brion, Jean Daniel; Liu, Jian Miao; Bignon, Jerome; Bakala, Joanna
PATENT ASSIGNEE(S):	Centre National de la Recherche Scientifique (CNRS), Fr.
SOURCE:	Fr. Demande, 68pp. CODEN: FRXXBL
DOCUMENT TYPE:	Patent
LANGUAGE:	French

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2932180	A1	20091211	FR 2008-53694	20080604
WO 2009147217	A1	20091210	WO 2009-EP56885	20090604

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: FR 2008-53694 A 20080604
GI



I



II

AB Dihydro-iso-CA-4 analogs I [R1, R3 = MeO substituted with fluorine; R2, R4 = H, MeO substituted with fluorine; Z = aryl, heteroaryl; X = N, CH; Z1 = H, F; Z2 = H, F, (C1-C4) alkyl, CN, SO3R9, CO2R15, COR15; R9 = (C1-C4) alkyl, aryl, heteroaryl; R15 = H, (C1-C4) alkyl, aryl, heteroaryl, (CH2)mCO2H, (CH2)mNR7R8, m = 1-3; R7, R8 = H, (C1-C4) alkyl, aryl, heteroaryl] were prepared as antitumor agents and tubulin polymerization inhibitors. For example, reacting (trimethoxyphenyl)(hydroxymethoxyphenyl)ethene II (R = H, Y = CH2) with ClCONEt2 gave II (R = CONEt2, Y = CH2) which was hydrogenated to give II (R = CONEt2, Y = H,H). Several compds. were tested for cytotoxic activity against colorectal carcinoma, lung cancer and leukemia. The compds. are also useful as tubulin polymerization inhibitors and antivascular compds.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1250046 CAPLUS
DOCUMENT NUMBER: 149:448110
TITLE: Preparation of Iso CA-4 and analogs as potent cytotoxic agents and inhibitors of polymerization of tubulin
INVENTOR(S): Alami, Mouad; Brion, Jean-Daniel; Provot, Olivier; Peyrat, Jean-Francois; Messaoudi, Samir; Hamze, Abdallah; Giraud, Anne; Bignon, Jerome; Bakala, Joanna; Liu, Jian-Miao
PATENT ASSIGNEE(S): Centre National De La Recherche Scientifique, Fr.
SOURCE: PCT Int. Appl., 78pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008122620	A1	20081016	WO 2008-EP54118	20080404
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
FR 2914640	A1	20081010	FR 2007-54280	20070404
EP 2142493	A1	20100113	EP 2008-735856	20080404
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR				
US 20100129471	A1	20100527	US 2009-594495	20091002

PRIORITY APPLN. INFO.: FR 2007-54280 A 20070404
WO 2008-EP54118 W 20080404

OTHER SOURCE(S): MARPAT 149:448110
GI



I



II



III

AB Isocombretastatin A-4 and analogs I [R1, R2, R3 = methoxy (possibly substituted by one or more fluorine atoms); R5 = R6 = hydrogen or fluorine; A = ring chosen from (un)substiututed aryls and heteroaryls]. The process for the preparation of I comprises: (a) reaction of acetophenone derivative II with an organometallic compound, A-M [M = alkali metal or earth alkaline metal substituted with a halogen]; and (b) reaction of the resulting phenylethanol derivative III with an acid to form I. Thus, Iso-CA-4 [I; A = C6H3OH-3-OMe-4, R1 = R2 = R3 = OMe, R4 = R5 = R6 = H (IV)] was prepared from 3,4,5-trimethoxyacetophenone (II; R1 = R2 = R3 = OMe, R4 = R5 = R6 = H) via reaction in PhMe with tert-butyl(5-lithio-2-methoxyphenoxy)dimethylsilane [prepared from tert-butyl(5-iodo-2-methoxyphenoxy)dimethylsilane via lithiation with Me3CLi in hexane], dehydration of III with p-toluenesulfonic acid in CH2C12, and desilylation with K2CO3 in MeOH. The cytotoxic activity of IV was determined [IC50 = 2-4 nM vs. HCT116; IC50 = 5 nM vs. K562 cells; IC50 = 2 nM vs. B16F10 cells; IC50 = 8 nM vs. U87 cells; IC50 = 8 nM vs. A549 cells; IC50 = 4.5 nM vs. M435 cells; IC50 = 4 nM vs. M231 cells; IC50 =

2.2 μM vs tubulin polymerization].
OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:473431 CAPLUS
DOCUMENT NUMBER: 148:463206
TITLE: oncolytic viruses and antiangiogenic agents in the treatment of cancer
INVENTOR(S): Karrasch, Matthias; Mescheder, Axel
PATENT ASSIGNEE(S): Medigene AG, Germany
SOURCE: PCT Int. Appl., 69pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008043576	A1	20080417	WO 2007-EP8930	20071015
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 2073823	A1	20090701	EP 2007-819001	20071015
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
US 20090317456	A1	20091224	US 2009-445019	20090722
PRIORITY APPLN. INFO.:			US 2006-851598P P	20061013
			WO 2007-EP8930 W	20071015

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The invention relates to a combination of at least one oncolytic virus and at least one antiangiogenic agent and to the use of this combination in tumor therapy. Intraarterial infusions of oncolytic virus NV1020 to a patient with progressive metastatic colorectal adenocarcinoma followed by CPT-11 plus cetuximab resulted in stabilization of the disease at 6 mo post treatment.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:984120 CAPLUS
DOCUMENT NUMBER: 143:279360
TITLE: Methods of detecting CD133 antigen (AC133) expression level and use as biomarker for human cancer diagnosis and therapy monitor
INVENTOR(S): Penning, Maarten Tjerk; Van den Broek, Sebastiaan Johannes Jacobus; Voest, Emile Eugene; Beerepoot, Laurens Victor; Mehra, Niven
PATENT ASSIGNEE(S): Primagen Holding B. V., Neth.; UMC Utrecht Holding B.

V.
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005083123	A1	20050909	WO 2005-NL155	20050302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1571225	A1	20050907	EP 2004-75686	20040302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CA 2558604	A1	20050909	CA 2005-2558604	20050302
EP 1725679	A1	20061129	EP 2005-710924	20050302
EP 1725679	B1	20090603		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
AT 432997	T	20090615	AT 2005-710924	20050302
US 20070077578	A1	20070405	US 2006-514345	20060831
US 20090098563	A1	20090416	US 2008-284203	20080919

PRIORITY APPLN. INFO.:	EP 2004-75686	A	20040302
	US 2004-549450P	P	20040302
	EP 2005-710924	A	20050302
	WO 2005-NL155	W	20050302
	US 2006-514345	B1	20060831

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB This invention provides methods of detecting CD133 antigen (AC133) expression level and use as a biomarker for human cancer diagnosis and therapy monitor. Blood anal. including number of circulating endothelial cells and expression levels of human genes AC133 (CD133), EST032 and U1A evaluated by NASBA anal., were determined prior to and during chemotherapy using drugs such as angiostatin or PrimMed01, gemcitabine, and cisplatin, for a wide range of human tumor types. A use of a nucleic acid mol. comprising at least part of a sequence of AC133 or an analog thereof for monitoring a treatment of an individual suffering from a disease is also provided, as well as a diagnostic kit comprising such nucleic acid mol.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:975665 CAPLUS
DOCUMENT NUMBER: 143:264929
TITLE: Methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases
INVENTOR(S): Penning, Maarten Tjerk; Beerepoot, Laurens Victor; Van Den Broek, Sebastiaan Johannes Jacobus; Mehra, Niven; Voest, Emile Eugene
PATENT ASSIGNEE(S): Primagen Holding B.V., Neth.; UMC Utrecht Holding B.V.
SOURCE: Eur. Pat. Appl., 28 pp.

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1571225	A1	20050907	EP 2004-75686	20040302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CA 2558604	A1	20050909	CA 2005-2558604	20050302
WO 2005083123	A1	20050909	WO 2005-NL155	20050302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1725679	A1	20061129	EP 2005-710924	20050302
EP 1725679	B1	20090603		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
AT 432997	T	20090615	AT 2005-710924	20050302

PRIORITY APPLN. INFO.:
EP 2004-75686 A 20040302
US 2004-549450P P 20040302
WO 2005-NL155 W 20050302

AB The invention provides methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases. AC133 antigen mRNA may be quantitated by PCR, RT-PCR, NASBA, SDA, TMA, bDNA or rolling circle amplification. Diseases include cancer and heart disease, high blood pressure, ischemia, stroke, psoriasis, Crohn's disease, rheumatoid arthritis, endometriosis, atherosclerosis, obesity, diabetes mellitus, diabetic retinopathy, macular degeneration, Alzheimer's disease, Peutz Jegher's syndrome, multiple sclerosis, systemic lupus erythematosus, Wegener's granulomatosis, vasculitis, sickle cell disease, thalassemia and angina.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:202462 CAPLUS
DOCUMENT NUMBER: 138:226761
TITLE: Synergistic anticancer combinations containing 5,6-dimethylxanthenone-4-acetic acid
INVENTOR(S): Wilson, William Robert; Siim, Bronwyn Gae
PATENT ASSIGNEE(S): Cancer Research Technology Limited, UK
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO	2003020259	A2	20030313	WO 2002-GB4025	20020903
WO	2003020259	A3	20030417		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA	2458459	A1	20030313	CA 2002-2458459	20020903
AU	2002324143	A1	20030318	AU 2002-324143	20020903
AU	2002324143	B2	20070913		
EP	1423105	A2	20040602	EP 2002-758562	20020903
EP	1423105	B1	20081203		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR	2002012258	A	20041019	BR 2002-12258	20020903
JP	2005509599	T	20050414	JP 2003-524567	20020903
CN	1708296	A	20051214	CN 2002-817257	20020903
CN	100536840	C	20090909		
NZ	531045	A	20060831	NZ 2002-531045	20020903
EP	1759694	A2	20070307	EP 2006-77049	20020903
EP	1759694	A3	20090218		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK, RO, SI				
NZ	546573	A	20070531	NZ 2002-546573	20020903
CN	1994287	A	20070711	CN 2006-10151393	20020903
NZ	554093	A	20080731	NZ 2002-554093	20020903
AT	415963	T	20081215	AT 2002-758562	20020903
PT	1423105	E	20090309	PT 2002-758562	20020903
ES	2321283	T3	20090604	ES 2002-758562	20020903
NZ	567456	A	20090828	NZ 2002-567456	20020903
CN	101596186	A	20091209	CN 2009-10160409	20020903
CN	101596187	A	20091209	CN 2009-10160410	20020903
CN	101607087	A	20091223	CN 2009-10160408	20020903
NZ	576925	A	20100730	NZ 2002-576925	20020903
NO	2004000591	A	20040430	NO 2004-591	20040210
ZA	2004001078	A	20050415	ZA 2004-1078	20040210
US	20040204480	A1	20041014	US 2004-790943	20040302
MX	2004002004	A	20050217	MX 2004-2004	20040302
IN	2004CN00684	A	20060113	IN 2004-CN684	20040402
IN	228620	A1	20090320		
AU	2007202083	A1	20070531	AU 2007-202083	20070509
AU	2007202083	B2	20090820		
US	20080070847	A1	20080320	US 2007-830650	20070730
US	20080070848	A1	20080320	US 2007-830659	20070730
US	20080070886	A1	20080320	US 2007-830668	20070730
US	20080070849	A1	20080320	US 2007-830677	20070730
IN	2008CN02044	A	20090911	IN 2008-CN2044	20080424
JP	2009263371	A	20091112	JP 2009-133903	20090603
AU	2009202760	A1	20090730	AU 2009-202760	20090708
IN	2009CN06058	A	20100226	IN 2009-CN6058	20091014

PRIORITY APPLN. INFO.:

GB 2001-21285	A	20010903
AU 2002-324143	A3	20020903
CN 2002-817257	A3	20020903
EP 2002-758562	A3	20020903
JP 2003-524567	A3	20020903
WO 2002-GB4025	W	20020903

```
                                        US 2004-790943      A1 20040302
                                        IN 2004-CN684       A3 20040402
                                        AU 2007-202083      A3 20070509
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB   The present invention relates to synergistic combinations of the
     5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from
     platinum compds., Vinca alkaloids, alkylating agents, anthracyclines,
     topoisomerase I inhibitors, antimetabolites and topoisomerase II
     inhibitors, which have antitumor activity.  More particularly, the
     invention is concerned with the use of such combinations in the treatment
     of cancer and pharmaceutical compds. containing the combinations.  The
     antitumor activity and host toxicity of DMXAA/cytotoxic drug combinations
     was assessed by varying the dose of chemotherapeutic drug up to the
     toxicity limit, with co-administration of a fixed DMXAA dose (80
     μmol/kg, ca. 80% of MTD), and evaluating subsequent tumor growth delay.
     Of the 7 drugs investigated, 4 (doxorubicin, 5-fluorouracil,
     cyclophosphamide and cisplatin) had appreciable activity against this
     tumor as indicated by dose-response relationships providing significant
     slopes by linear regression, and highly significant growth delays of 10
     days at their MTDs.
OS.CITING REF COUNT:     4     THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
                               (4 CITINGS)
REFERENCE COUNT:         3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his

     (FILE 'HOME' ENTERED AT 13:24:45 ON 30 SEP 2010)

     FILE 'REGISTRY' ENTERED AT 13:24:56 ON 30 SEP 2010
L1            3 S DMXAA

     FILE 'CAPLUS' ENTERED AT 13:25:13 ON 30 SEP 2010
L2          216 S L1

     FILE 'REGISTRY' ENTERED AT 13:25:20 ON 30 SEP 2010
L3           15 S GEMCITABINE

     FILE 'CAPLUS' ENTERED AT 13:25:29 ON 30 SEP 2010
L4         6347 S L3
L5            9 S L2 AND L4
L6            9 DUP REM L5 (0 DUPLICATES REMOVED)

=> s l2 and (cancer or tumor or neoplasm)
        475250 CANCER
         69792 CANCERS
        492307 CANCER
                  (CANCER OR CANCERS)
        563489 TUMOR
        200841 TUMORS
        624376 TUMOR
                  (TUMOR OR TUMORS)
          5084 TUMOUR
          1909 TUMOURS
          6865 TUMOUR
                  (TUMOUR OR TUMOURS)
        624829 TUMOR
                  (TUMOR OR TUMOUR)
        619673 NEOPLASM
         39180 NEOPLASMS
        637180 NEOPLASM
```

```
                (NEOPLASM OR NEOPLASMS)
L7          196 L2 AND (CANCER OR TUMOR OR NEOPLASM)

=> s l7 and ad<20020903
       4434436 AD<20020903
                 (AD<20020903)
L8           10 L7 AND AD<20020903

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9           10 DUP REM L8 (0 DUPLICATES REMOVED)

=> d l9 1-10 ibib abs

L9   ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2005:527410  CAPLUS
DOCUMENT NUMBER:          143:53472
TITLE:                    Anticancer combinations of xanthenone-type compounds
                          and NSAIDs
INVENTOR(S):              Wang, Liang-Chuan Steve; Paxton, James William; Ching,
                          Lai-Ming; Baguley, Bruce Charles; Kestell, Philip
PATENT ASSIGNEE(S):       Cancer Research Technology Limited, UK
SOURCE:                   U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of Appl.
                          No. PCT/GB03/01320.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    -------------------     --------
     US 20050131059       A1    20050616    US 2004-946833          20040922
     US 7462642           B2    20081209
     GB 2386836           A     20031001    GB 2002-6839            20020322 <--
     GB 2386836           B     20060726
     WO 2003080044        A1    20031002    WO 2003-GB1320          20030320
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 20090062377       A1    20090305    US 2008-264197          20081103
PRIORITY APPLN. INFO.:                     GB 2002-6839         A  20020322
                                           WO 2003-GB1320       A2 20030320
                                           US 2004-946833       A3 20040922
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S):          MARPAT 143:53472
GI
```



I

AB The invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compns. containing said combinations. Method of modulating neoplastic growth comprises synergistically administering to a mammal, including humans, (i) a compound of formula I [(a) R1-3 = H, C1-6 alkyl, halo, CF3, CN, NO2, NH2, OH, OR, NHCOR, NHSO2R, SR, SO2R, NHR; R = C1-6 alkyl or alkoxy; R4-5 = 6-membered aromatic ring substituted by R3 and (B)-CO2H, (B) = linear/branched (un)substituted (ethylenically un)saturated C1-6 alkyl; (b) R1 = H, C1-6 alkyl or alkoxy; R2 = (B)-CO2H; R4-5 = H, Ph, C1-6 alkyl, cycloalkyl, thenyl, furyl, naphthyl, aralkyl; R2 = (B)-CO2H], including DMXAA, or its salt or ester, and (ii) either concomitantly or sequentially administering a non-steroidal anti-inflammatory drug (NSAID), e.g. diclofenac, salicylate, ibuprofen, celecoxib or rofecoxib, at an amount less than that required to substantially alter the plasma pharmacokinetics of compound I in the mammal. For example, coadministration of diclofenac (5 mg/kg) with DMXAA (25 mg/kg) led to an improved antitumor activity in colon 38 tumor -bearing mice. Diclofenac alone had no effect on the growth of colon 38 tumors, DMXAA alone produced a growth delay of about 6 days, but none of the mice were cured, while the combination showed 100% cure. In addition to the use of such combinations in the treatment of cancer , the invention also covers pharmaceutical compns. containing said combinations and kits comprising such combinations for simultaneous, sep., or sequential use.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L9 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:776826 CAPLUS

DOCUMENT NUMBER: 139:271036

TITLE: Anticancer combinations of xanthenone-type compounds and NSAIDs

INVENTOR(S): Wang, Liang-chuan Steve; Paxton, James William; Ching, Lai-ming; Baguley, Bruce Charles; Kestell, Philip

PATENT ASSIGNEE(S): Cancer Research Technology Limited, UK

SOURCE: Brit. UK Pat. Appl., 31 pp.
CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2386836	A	20031001	GB 2002-6839	20020322 <--
GB 2386836	B	20060726		
WO 2003080044	A1	20031002	WO 2003-GB1320	20030320

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003217035	A1	20031008	AU 2003-217035		20030320
EP 1487433	A1	20041222	EP 2003-712423		20030320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005526786	T	20050908	JP 2003-577872		20030320
US 20050131059	A1	20050616	US 2004-946833		20040922
US 7462642	B2	20081209			
US 20090062377	A1	20090305	US 2008-264197		20081103
PRIORITY APPLN. INFO.:			GB 2002-6839	A	20020322
			WO 2003-GB1320	W	20030320
			US 2004-946833	A3	20040922

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 139:271036
GI



I

AB Method of modulating neoplastic growth comprises synergistically administering to a mammal, including humans, (i) a compound of formula I [(a) R1-3 = H, C1-6 alkyl, halo, CF3, CN, NO2, NH2, OH, OR, NHCOR, NHSO2R, SR, SO2R, NHR; R = C1-6 alkyl or alkoxy; R4-5 = 6-membered aromatic ring substituted by R3 and (B)-CO2H, (B) = linear/branched (un)substituted (ethylenically un)saturated C1-6 alkyl; (b) R1 = H, C1-6 alkyl or alkoxy; R2 = (B)-CO2H; R4-5 = H, Ph, C1-6 alkyl, cycloalkyl, thenyl, furyl, naphthyl, aralkyl; R2 = (B)-CO2H], including DMXAA, or its salt or ester, and (ii) either concomitantly or sequentially administering a non-steroidal anti-inflammatory drug (NSAID), e.g. diclofenac, salicylate, ibuprofen, celecoxib or rofecoxib, at an amount less than that required to substantially alter the plasma pharmacokinetics of compound I in the mammal. For example, coadministration of diclofenac (5 mg/kg) with DMXAA (25 mg/kg) led to an improved antitumor activity in colon 38 tumor -bearing mice. Diclofenac alone had no effect on the growth of colon 38 tumors, DMXAA alone produced a growth delay of about 6 days, but none of the mice were cured, while the combination showed 100% cure.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:172911 CAPLUS
DOCUMENT NUMBER: 138:198597
TITLE: Anti-cancer combinations of dmxaa and paclitaxel or docetaxel
INVENTOR(S): Wilson, William Robert
PATENT ASSIGNEE(S): Cancer Research Ventures Limited, UK
SOURCE: Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1287854	A1	20030305	EP 2001-307370	20010830 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 311228	T	20051215	AT 2001-307370	20010830 <--
ES 2252160	T3	20060516	ES 2001-307370	20010830 <--
PRIORITY APPLN. INFO.:			EP 2001-307370 A	20010830

AB The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and taxanes, in particular paclitaxel and or docetaxel which have anti-tumor activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compns. containing said combinations.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:107103 CAPLUS
DOCUMENT NUMBER: 136:145217
TITLE: Xanthenone acetic acid compound-TNF modulator combination for cancer treatment
INVENTOR(S): Baguley, Bruce Charles; Ching, Lai-Ming; Philpott, Martin
PATENT ASSIGNEE(S): Cancer Research Ventures Limited, UK
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002009700	A1	20020207	WO 2001-NZ154	20010727 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001082717	A	20020213	AU 2001-82717	20010727 <--
EP 1311262	A1	20030521	EP 2001-961455	20010727 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004505047	T	20040219	JP 2002-515253	20010727 <--
US 20040087611	A1	20040506	US 2003-341736	20030114
US 7510830	B2	20090331		
PRIORITY APPLN. INFO.:			NZ 2000-506060 A	20000728
			WO 2001-NZ154 W	20010727

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 136:145217
AB The invention provides a method of treating cancer and compns. of use in such a method, the method including administering, either

sequentially or simultaneously, (i) a compound of the xanthenone acetic acid group of compds., and (ii) at least one compound selected from compds. which modulate TNF production and compds. which act on biochem. pathways leading to TNF synthesis, the composition including a combination of (i) and (ii) above together with acceptable pharmaceutical carriers and/or vehicles.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:693118 CAPLUS
DOCUMENT NUMBER: 137:195564
TITLE: Use of xanthenone-4-acetic acid in the manufacture of a medicament in the treatment of hyperproliferative disorders
INVENTOR(S): Bellnier, David A.; Dougherty, Thomas J.
PATENT ASSIGNEE(S): Health Research, Inc., USA
SOURCE: Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1238666	A2	20020911	EP 2002-4592	20020228 <--
EP 1238666	A3	20040107		
EP 1238666	B1	20050511		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20020128303	A1	20020912	US 2001-801163	20010307 <--
US 6495585	B2	20021217		
AT 295163	T	20050515	AT 2002-4592	20020228 <--
JP 2002325853	A	20021112	JP 2002-61784	20020307 <--
PRIORITY APPLN. INFO.:			US 2001-801163 A	20010307

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A novel method for treating undesired hyperproliferative tissue in a mammal. The method includes the steps of: injecting the mammal with a photodynamic compound having a selective uptake in the hyperproliferative tissue and which is activated at a particular light frequency; injecting the mammal with a xanthenone-4-acetic acid or a Group I metal, Group II metal or quaternary salt thereof near the time of maximum uptake of the photodynamic compound in the hyperproliferative tissue; and exposing the hyperproliferative tissue to light at the particular frequency that activates the photodynamic compound The method of the invention causes necrosis of the hyperproliferative tissue to an extent greater than can be obtained by either the photodynamic compound or xanthenone-4-acetic acid alone. Further and surprisingly the method enhances immune response of the mammal to the hyperproliferative tissue even after the photodynamic compound and xanthenone-4-acetic acid are no longer present in the mammal. Efficacy of a combination of 20 mg 5,6-dimethylxanthenone-4-acetic acid and 135 J/cm2 630 nm laser light against RIF-1 tumors in mice is shown.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:664509 CAPLUS

DOCUMENT NUMBER: 135:221279
TITLE: Combination of xanthenone derivatives and paclitaxel or docetaxel for treatment of cancer
INVENTOR(S): Wilson, William Robert
PATENT ASSIGNEE(S): Auckland UniServices Limited, N. Z.
SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001247459	A	20010911	JP 2000-232871	20000801 <--
US 20010027210	A1	20011004	US 2001-774002	20010131 <--
US 6667337	B2	20031223		

PRIORITY APPLN. INFO.: NZ 2000-503199 A 20000303
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 135:221279
GI



I

AB Xanthenone derivs. (I; R1, R2, R3 = H, C1-5 alkyl, halogen, CF3, CN, NO2, NH2, OH, OR, NHCOR, NHSO2R, SR, SO2R, NHR, with R = (substituted)alkyl) and their pharmaceutically acceptable salts in combination with paclitaxel or docetaxel are claimed for treatment of cancer. The synergistic antitumor effects of the combinations were tested in mice.
OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L9 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:900440 CAPLUS
DOCUMENT NUMBER: 134:66132
TITLE: Cancer therapy with an immunotherapeutic agent in conjunction with a tumor growth-restricting agent
INVENTOR(S): Krissansen, Geoffrey Wayne; Kanwar, Jagat Rakesh; Ching, Lai-ming
PATENT ASSIGNEE(S): Auckland Uniservices Limited, N. Z.
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000076497	A1	20001221	WO 2000-NZ98	20000614 <--

```
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
            CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
            ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
            LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
            SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
            ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
            CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    EP 1189611          A1    20020327    EP 2000-942571          20000614 <--
    EP 1189611          B1    20060503
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, CY
    JP 2003501460       T     20030114    JP 2001-502830          20000614 <--
    NZ 516564           A     20031031    NZ 2000-516564          20000614 <--
    AT 324888           T     20060615    AT 2000-942571          20000614 <--
    ES 2265948          T3    20070301    ES 2000-942571          20000614 <--
    US 20030003092      A1    20030102    US 2001-14887           20011211 <--
    US 20040086498      A9    20040506
PRIORITY APPLN. INFO.:                    NZ 1999-336259      A   19990614
                                          WO 2000-NZ98        W   20000614
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB  A method is provided for treating mammals, including humans, with advanced
    or large-tumor burdens.  The method involves administering an
    immunotherapeutic agent in conjunction with a tumor
    growth-restricting agent, in amts. effective to eradicate any advanced or
    large tumors present.  In preferred embodiments, the
    immunotherapeutic agent comprises a T-cell co-stimulatory cell adhesion
    mol. (CAM) or a mammalian expression vector containing DNA which encodes a
    T-cell co-stimulatory CAM, such as B7.1, and the tumor growth
    restricting agent is flavone acetic acid, 5,6-dimethyl-xanthenone-4-acetic
    acid, or an agent which disrupts the expression or activity of
    hypoxia-inducible factor-1 (HIF-1).
OS.CITING REF COUNT:     13    THERE ARE 13 CAPLUS RECORDS THAT CITE THIS
                               RECORD (13 CITINGS)
REFERENCE COUNT:         9     THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9   ANSWER 8 OF 10  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:        1995:618127  CAPLUS
DOCUMENT NUMBER:         123:17878
ORIGINAL REFERENCE NO.:  123:3338h,3339a
TITLE:                   Pharmaceutical compositions containing nitric oxide
                         synthase inhibitors and anticancer agents
INVENTOR(S):             Thomsen, Lindy Louise; Knowles, Richard Graham;
                         Moncada, Salvador Enrique
PATENT ASSIGNEE(S):      Wellcome Foundation Ltd., UK
SOURCE:                  PCT Int. Appl., 14 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ----------          ----   --------    -------------------     --------
     WO 9509621           A1    19950413    WO 1994-GB2146          19941004 <--
         W:  AU, BR, CA, CN, CZ, FI, GE, HU, JP, KR, KZ, LT, NO, NZ, PL, RU,
             SI, SK, UA, US, UZ
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     AU 9477876           A     19950501    AU 1994-77876           19941004 <--
     ZA 9407754           A     19960404    ZA 1994-7754            19941004 <--
```

PRIORITY APPLN. INFO.: GB 1993-20484 A 19931005
WO 1994-GB2146 W 19941004
OTHER SOURCE(S): MARPAT 123:17878
GI



AB A pharmaceutical composition for treatment of cancer or reducing the tumor burden comprises a nitric oxide synthase inhibitor in combination with a cytokine-releasing anticancer agent. The anticancer agents are derivs. of 5,6-dimethylxanthenone acetic acid (DMX) I (R1 = alkyl, halogen, Ph, CF3, CN, NO2, NH2, CH2CO2H, OR2, SR2, SO2R2, NHR2, etc; R2 = alkyl, amino, methoxy). Tumor regressions induced by treatment with DMX (30 mg/kg i.p.) were not inhibited by the NO synthase inhibitor L-N-iminoethylornithine (L-NIO) (30 mg/kg s.c. followed by 100 mg/kg s.c. 8 h later) despite the fact that the dose used completely inhibited the increased NO generation. L-NIO increased systemic arterial pressure within 10 min of injection.
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L9 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1995:297673 CAPLUS
DOCUMENT NUMBER: 122:64319
ORIGINAL REFERENCE NO.: 122:12175a,12178a
TITLE: Cancer therapy, using antibody conjugates, in combination with a vasoactive agent
INVENTOR(S): Pedley, Rosamund Barbara; Begent, Richard Henry John
PATENT ASSIGNEE(S): Cancer Research Campaign Technology Ltd., UK
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9423753	A1	19941027	WO 1994-GB831	19940420 <--

W: JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRIORITY APPLN. INFO.: GB 1993-8166 A 19930420
OTHER SOURCE(S): MARPAT 122:64319
AB The invention provides a two component system for the treatment of cancer comprising: (i) a tumor-directed antibody linked to a toxic agent or linked to an enzyme capable of converting a prodrug to a toxic agent; and (ii) an agent having the ability to restrict blood flow at the site of a tumor. Preferably the agent is a flavonoid derivative such as 5,6-dimethylxanthenone acetic acid or flavone acetic acid.
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1989:8048 CAPLUS
DOCUMENT NUMBER: 110:8048
ORIGINAL REFERENCE NO.: 110:1475a,1478a
TITLE: Antitumor and antibacterial xanthenone-4-acetic acids and process for their preparation
INVENTOR(S): Denny, William Alexander; Baguley, Bruce Charles; Atwell, Graham John; Rewcastle, Gordon William
PATENT ASSIGNEE(S): DFC New Zealand Ltd., N. Z.
SOURCE: Eur. Pat. Appl., 33 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 278176	A2	19880817	EP 1987-311274	19871222 <--
EP 278176	A3	19900328		
EP 278176	B1	19940309		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 63295570	A	19881201	JP 1987-325109	19871222 <--
AT 102616	T	19940315	AT 1987-311274	19871222 <--
ES 2061518	T3	19941216	ES 1987-311274	19871222 <--
US 5281620	A	19940125	US 1992-912466	19920713 <--
PRIORITY APPLN. INFO.:			NZ 1986-218781 A	19861223
			EP 1987-311274 A	19871222
			US 1987-137271 B1	19871223
			US 1990-554974 B1	19900716
			US 1991-793506 B1	19911115

OTHER SOURCE(S): MARPAT 110:8048
GI



I

AB The title compds. I (R1 = 1 or 2 of lower alkyl, halo, Ph, CF3, cyanoN, NO2, NH2, OH, etc.), useful as antitumor and antibacterial agents, were prepared Reaction of 2-MeC6H4OH with diphenyliodonium-2-carboxylate in the presence of Cu(OAc)2, followed by cyclocondensation, bromination, cyanation, and hydrolysis gave xanthenone-4-acetic acid (II). At 220 mg/kg i.p., II caused extensive hemorrhagic necrosis in Colon 38 tumors in mice.
OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)

=> file medline embase biosis
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	69.14	88.14

```
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                    ENTRY    SESSION
CA SUBSCRIBER PRICE                                -16.15     -16.15

FILE 'MEDLINE' ENTERED AT 13:26:51 ON 30 SEP 2010

FILE 'EMBASE' ENTERED AT 13:26:51 ON 30 SEP 2010
Copyright (c) 2010 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 13:26:51 ON 30 SEP 2010
Copyright (c) 2010 The Thomson Corporation

=> s l2 or l2<chem>

   SmartSELECT INITIATED
New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details


COST IN U.S. DOLLARS                             SINCE FILE      TOTAL
                                                    ENTRY    SESSION
FULL ESTIMATED COST                                 3.33      91.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                    ENTRY    SESSION
CA SUBSCRIBER PRICE                                 0.00     -16.15

FILE 'CAPLUS' ENTERED AT 13:26:57 ON 30 SEP 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

SET SMARTSELECT ON
SET COMMAND COMPLETED

SEL L2 1- CHEM
'CHEM' IS NOT A VALID FIELD CODE FOR FILE 'CAPLUS'
The following are valid field codes:
AB ------ Abstract Text
AC ------ Patent Application Country
AD ------ Patent Application Date
AI ------ Patent Application Information
AN ------ Accession Number
AP ------ Patent Application Number
APPS ---- Patent Application and Priority Number
AU ------ Author or Patent Inventor
AY ------ Patent Application Year
CC ------ CA Classification Codes
CS ------ Corporate Source or Patent Assignee
CS.DIV -- Corporate Source, Division
CS.ORG -- Corporate Source, Organization Name
CT ------ Controlled Term
CYA ----- Country Name of Author
DS ------ Designated States (Patents)
DT ------ Document Type
FAN ----- Family Accession Number
FS ------ File Segment
GENBANK - GENBANK Number
IC ------ International Patent Classification (IPC)
ICA ----- Additional (Supplementary) IPC
ICI ----- Index (Complementary) IPC
```

```
ICM ----- Main IPC
ICS ----- Secondary IPC
IN ------ Inventor Name
ISN ----- International Standard (Document) Number
ISSN----- ISSN
IPC ----- International Patent Classifications
IT ------ Index Entries
JT ------ Journal Title
LA ------ Language
NCL------ National Patent Classification Code
OS ------ Other Source
PA ------ Patent Assignee
PATS----- Patent Numbers
PC ------ Patent Country
PCS ----- Patent Countries
PD ------ Publication Date
PI ------ Patent Information
PK ------ Kind of Patent
PN ------ Patent Number
PRAI ---- Patent Priority Information
PRC ----- Patent Priority Country
PRD ----- Patent Priority Date
PRN ----- Patent Priority Number
PRY ----- Patent Priority Year
PY ------ Publication Year of Original Document
RE ------ Reference
REC ----- Reference Count
RAN.CA -- Reference CA File Accession Number
RAN.CAPLUS --- Reference CAPLus File Accession Nummber
RAN.MEDLINE -- Reference MEDLINE File Accession Number
RAN.ALL ------ Reference Accession Numbers for All Files
RIN ----- Reference Inventor
RAU ----- Reference Author
RWK ----- Reference Work
RPG ----- Reference Page Number
RPN ----- Reference Patent Number
RPY ----- Reference Publication Year
RVL ----- Reference Publication Volume
RL ------ Roles
RN ------ CAS Registry Number
SO ------ Source
ST ------ Supplementary Terms (CA Keywords)
SX ------ Chemical Abstract Section Cross-Reference Code
TI ------ Title of Document
ENTER DISPLAY CODE (TI) OR ?:ti
L10         SEL L2 1- TI :     777 TERMS

SET SMARTSELECT OFF
SET COMMAND COMPLETED


COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    15.50     106.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -16.15

FILE 'MEDLINE' ENTERED AT 13:27:06 ON 30 SEP 2010

FILE 'EMBASE' ENTERED AT 13:27:06 ON 30 SEP 2010
```

FILE 'BIOSIS' ENTERED AT 13:27:06 ON 30 SEP 2010

S L2 OR L10

SYSTEM LIMITS EXCEEDED - SEARCH ENDED
=> d his

(FILE 'HOME' ENTERED AT 13:24:45 ON 30 SEP 2010)

FILE 'REGISTRY' ENTERED AT 13:24:56 ON 30 SEP 2010
L1 3 S DMXAA

FILE 'CAPLUS' ENTERED AT 13:25:13 ON 30 SEP 2010
L2 216 S L1

FILE 'REGISTRY' ENTERED AT 13:25:20 ON 30 SEP 2010
L3 15 S GEMCITABINE

FILE 'CAPLUS' ENTERED AT 13:25:29 ON 30 SEP 2010
L4 6347 S L3
L5 9 S L2 AND L4
L6 9 DUP REM L5 (0 DUPLICATES REMOVED)
L7 196 S L2 AND (CANCER OR TUMOR OR NEOPLASM)
L8 10 S L7 AND AD<20020903
L9 10 DUP REM L8 (0 DUPLICATES REMOVED)

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 13:26:51 ON 30 SEP 2010

FILE 'CAPLUS' ENTERED AT 13:26:57 ON 30 SEP 2010
SET SMARTSELECT ON
L10 SEL L2 1- TI : 777 TERMS
SET SMARTSELECT OFF

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 13:27:06 ON 30 SEP 2010

=> s l1 or l1<chem>

SmartSELECT INITIATED
New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.33	110.30

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-16.15

FILE 'REGISTRY' ENTERED AT 13:27:27 ON 30 SEP 2010

SET SMARTSELECT ON
SET COMMAND COMPLETED

```
SEL L1 1- CHEM
L11          SEL L1 1- CHEM :       12 TERMS

SET SMARTSELECT OFF
SET COMMAND COMPLETED


COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    15.49     125.79

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -16.15

FILE 'MEDLINE' ENTERED AT 13:27:28 ON 30 SEP 2010

FILE 'EMBASE' ENTERED AT 13:27:28 ON 30 SEP 2010
Copyright (c) 2010 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 13:27:28 ON 30 SEP 2010
Copyright (c) 2010 The Thomson Corporation

S L1 OR L11


L13         741 L1 OR L12

=> s l13 and (cancer or tumor or tumour or neoplasm)
L14         676 L13 AND (CANCER OR TUMOR OR TUMOUR OR NEOPLASM)

=> s l14 and pd<20020903
L15         240 L14 AND PD<20020903

=> dup rem l15
PROCESSING COMPLETED FOR L15
L16         115 DUP REM L15 (125 DUPLICATES REMOVED)

=> s l16 and gemcitabine
L17           0 L16 AND GEMCITABINE

=> s l16 and (lung or pancrea?)
L18           9 L16 AND (LUNG OR PANCREA?)

=> d l18 1-9 ibib abs

L18  ANSWER 1 OF 9      MEDLINE on STN
ACCESSION NUMBER:    2001189654      MEDLINE
DOCUMENT NUMBER:     PubMed ID: 11280751
TITLE:               Vascular attack by 5,6-
                     dimethylxanthenone-4-acetic
                     acid combined with B7.1 (CD80)-mediated
                     immunotherapy overcomes immune resistance and leads to the
                     eradication of large tumors and multiple
                     tumor foci.
AUTHOR:              Kanwar J R; Kanwar R K; Pandey S; Ching L M; Krissansen G W
CORPORATE SOURCE:    Department of Molecular Medicine, School of Medicine and
                     Health Science, University of Auckland, New Zealand.
SOURCE:              Cancer research, (2001 Mar 1) Vol. 61, No. 5, pp.
                     1948-56.
                     Journal code: 2984705R. ISSN: 0008-5472. L-ISSN: 0008-5472.
```

PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200104
ENTRY DATE: Entered STN: 25 Apr 2001
Last Updated on STN: 25 Apr 2001
Entered Medline: 19 Apr 2001

AB The promise of cancer immunotherapy is that it will not only eradicate primary tumors but will generate systemic antitumor immunity capable of destroying distant metastases. A major problem that must first be surmounted relates to the immune resistance of large tumors. Here we reveal that immune resistance can be overcome by combining immunotherapy with a concerted attack on the tumor vasculature. The functionally related antitumor drugs 5, 6-dimethylxanthenone-4-acetic
acid (DMXAA) and flavone acetic acid (FAA), which cause tumor vasculature collapse and tumor necrosis, were used to attack the tumor vasculature, whereas the T-cell costimulator B7.1 (CD80), which costimulates T-cell proliferation via the CD28 pathway, was used to stimulate antitumor immunity. The injection of cDNA (60-180 microg) encoding B7.1 into large EL-4 tumors (0.8 cm in diameter) established in C57BL/6 mice, followed 24 h later by i.p. administration of either DMXAA (25 mg/kg) or FAA (300 mg/kg), resulted in complete tumor eradication within 2-6 weeks. In contrast, monotherapies were ineffective. Both vascular attack and B7.1 immunotherapy led to up-regulation of heat shock protein 70 on stressed and dying tumor cells, potentially augmenting immunotherapy. Remarkably, large tumors took on the appearance of a wound that rapidly ameliorated, leaving perfectly healed skin. Combined therapy was mediated by CD8+ T cells and natural killer cells, accompanied by heightened and prolonged antitumor cytolytic activity ($P < 0.001$), and by a marked increase in tumor cell apoptosis. Cured animals completely rejected a challenge of 1 x 10(7) parental EL-4 tumor cells but not a challenge of 1 x 10(4) Lewis lung carcinoma cells, demonstrating that antitumor immunity was tumor specific. Adoptive transfer of 2 x 10(8) splenocytes from treated mice into recipients bearing established (0.8 cm in diameter) tumors resulted in rapid and complete tumor rejection within 3 weeks. Although DMXAA and B7.1 monotherapies are complicated by a narrow range of effective doses, combined therapy was less dosage dependent. Thus, a broad range of amounts of B7.1 cDNA were effective in combination with 25 mg/kg DMXAA. In contrast, DMXAA, which has a very narrow range of high active doses, was effective at a low dose (18 mg/kg) when administered with a large amount (180 microg) of B7.1 cDNA. Importantly, combinational therapy generated heightened antitumor immunity, such that gene transfer of B7.1 into one tumor, followed by systemic DMXAA treatment, led to the complete rejection of multiple untreated tumor nodules established in the opposing flank. These findings have important implications for the future direction and utility of cancer immunotherapies aimed at harnessing patients' immune responses to their own tumors.

L18 ANSWER 2 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2001182020 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11236926
TITLE: Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic
acid on blood perfusion in a murine tumour and normal tissues.

AUTHOR: Murata R; Overgaard J; Horsman M R
CORPORATE SOURCE: Danish Cancer Society, Department of Experimental Clinical Oncology, Aarhus University Hospital.. rumi@oncology.dk
SOURCE: International journal of radiation biology, (2001 Feb) Vol. 77, No. 2, pp. 195-204.
Journal code: 8809243. ISSN: 0955-3002. L-ISSN: 0955-3002.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals; Space Life Sciences
ENTRY MONTH: 200103
ENTRY DATE: Entered STN: 4 Apr 2001
Last Updated on STN: 4 Apr 2001
Entered Medline: 29 Mar 2001

AB PURPOSE: To compare the ability of combretastatin A-4 disodium phosphate (CA4DP) and 5,6-dimethylxanthenone-4
-acetic acid (DMXAA) to change tissue blood perfusion. MATERIALS AND METHODS: The tissues were a C3H mouse mammary carcinoma and various murine normal tissues, with perfusion measured using the 86RbCl extraction technique. RESULTS: CA4DP (250mg/kg; i.p.) reduced tumour perfusion to 34% of that seen in controls within 1 h of injection. It was maintained at this for at least 6 h, returning to control levels by 24 h. This decrease was dose-dependent. DMXAA (25mg/kg; i.p.) caused a 79% reduction in tumour perfusion 6h after injection; no recovery was observed even after 24 h. DMXAA showed no changes at doses below 10 mg/kg. Both CA4DP and DMXAA increased perfusion in the gut, kidney, bladder and lung, while decreasing splenic perfusion. CA4DP tended to decrease perfusion in muscle, while DMXAA increased liver perfusion. These changes in normal tissue perfusion were generally less than those changes seen in tumours. No significant changes were seen in skin. CONCLUSIONS: CA4DP and DMXAA produced a selective and significant reduction in tumour perfusion, but the pattern of change was different. These results suggest how these vascular targeting drugs should be combined with more conventional therapies.

L18 ANSWER 3 OF 9 MEDLINE on STN
ACCESSION NUMBER: 1998131981 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9472639
TITLE: Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid.
AUTHOR: Moilanen E; Thomsen L L; Miles D W; Happerfield D W; Knowles R G; Moncada S
CORPORATE SOURCE: Wellcome Research Laboratories, Beckenham, Kent, UK.
SOURCE: British journal of cancer, (1998) Vol. 77, No. 3, pp. 426-33.
Journal code: 0370635. ISSN: 0007-0920. L-ISSN: 0007-0920.
Report No.: NLM-PMC2151290.
PUB. COUNTRY: SCOTLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199802
ENTRY DATE: Entered STN: 12 Mar 1998
Last Updated on STN: 12 Mar 1998
Entered Medline: 27 Feb 1998

MEDLINE REFERENCE COUNT: 32 There are 32 cited references available in MEDLINE for this document.

AB An anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (5,6-MeXAA) induced nitric oxide synthase (NOS) in the tumour, spleen, thymus and small intestine, but not in the lung, liver, kidney, heart or skeletal muscle in B6D2F1 mice bearing subcutaneous colon 38 tumours. This pattern of induction is distinct from that caused by agents such as endotoxin, muramyl dipeptide or Corynebacterium parvum. The induction of NOS (iNOS) in the tumour was more persistent (maximal at 3 days) than in other tissues (maximal at 12 h). Immunohistochemical staining suggested that iNOS was located in macrophages and endothelial cells within and around the tumour. Treatment with 5,6-MeXAA also caused substantial increases in plasma nitrite and nitrate (NOx) concentrations that peaked at 8-12 h after 5,6-MeXAA. The increase in plasma NOx was prevented by a NOS inhibitor N-iminoethyl-L-ornithine (L-NIO), indicating that it was due to enhanced production of NO. Tumour-bearing mice were more responsive than controls to 5,6-MeXAA both in their plasma NOx increase and in their lower maximally tolerated dose. L-NIO was unable to prevent the complete tumour necrosis and regression caused by 5,6-MeXAA at a dose that substantially inhibited the increase of plasma NOx. In conclusion, the experimental anti-tumour agent 5,6-MeXAA induced NO synthesis in tumour-associated macrophages and in immunologically active tissues in parallel with its effects on tumour growth. The experiments with a non-selective NOS inhibitor L-NIO, however, suggest that NO is not a significant component in the mechanism of the anti-tumour action of 5,6-MeXAA in this particular model.

L18 ANSWER 4 OF 9 MEDLINE on STN
ACCESSION NUMBER: 1995298666 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7779712
TITLE: Preclinical in vitro and in vivo activity of 5, 6-dimethylxanthenone-4-acetic acid.
AUTHOR: Laws A L; Matthew A M; Double J A; Bibby M C
CORPORATE SOURCE: Clinical Oncology Unit, University of Bradford, UK.
SOURCE: British journal of cancer, (1995 Jun) Vol. 71, No. 6, pp. 1204-9.
Journal code: 0370635. ISSN: 0007-0920. L-ISSN: 0007-0920.
Report No.: NLM-PMC2033820.
PUB. COUNTRY: SCOTLAND: United Kingdom
DOCUMENT TYPE: (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199507
ENTRY DATE: Entered STN: 26 Jul 1995
Last Updated on STN: 6 Feb 1998
Entered Medline: 19 Jul 1995

MEDLINE REFERENCE COUNT: 36 There are 36 cited references available in MEDLINE for this document.

AB 5,6-Dimethylxanthenone-4-acetic acid (5,6-MeXAA) is a fused tricyclic analogue of flavone acetic acid (FAA) which was developed in an attempt to improve on the activity of FAA. Previous studies have shown 5,6-MeXAA to be curative in 80% of mice bearing colon 38 tumours and 12 times more dose potent than FAA. This investigation has demonstrated that a murine colon tumour cell line (MAC15A) is approximately 60 times more sensitive to 5,6-MeXAA than to FAA, although these differences were not seen in three human cell lines tested. 5,6-MeXAA caused significant blood flow

shutdown and haemorrhagic necrosis in subcutaneous MAC15A tumours in syngeneic and nude hosts, but measurable changes in tumour volume were seen only in syngeneic hosts. 5,6-MeXAA was inactive against intraperitoneal MAC15A but produced significant anti-tumour effects against the same cell line inoculated via an intravenous route. FAA has been shown previously to be inactive in this model. Interestingly, the effects against lung colonies were not accompanied by obvious necrotic changes, suggesting that they may be the result of increased direct cytotoxicity rather than an indirect host mechanism. Further studies to investigate the effects against systemic tumour deposits are under way.

L18 ANSWER 5 OF 9 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2004048446 EMBASE
TITLE: Beeson Gregory and Weil Gotshal & Manges Cancer Therapies Conference and Exhibition 2002: 20 February 2002, London, UK.
AUTHOR: Zarkowska, Tamara (correspondence)
CORPORATE SOURCE: Current Drugs Ltd., Middlesex House, 34-42 Cleveland Street, London W1T 4LB, United Kingdom. tamara.zarkowska@current-drugs.com
SOURCE: IDrugs, (Apr 2002) Vol. 5, No. 4, pp. 316-319. ISSN: 1369-7056 CODEN: IDRUFN
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Conference Article; (Conference paper)
FILE SEGMENT: 016 Cancer
022 Human Genetics
026 Immunology, Serology and Transplantation
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
LANGUAGE: English
ENTRY DATE: Entered STN: 12 Feb 2004
Last Updated on STN: 12 Feb 2004

L18 ANSWER 6 OF 9 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2003402999 EMBASE
TITLE: Bio 2002 - International Biotechnology Convention and Exhibition Novel cancer therapies: 9-12 June 2002, Toronto, Canada.
AUTHOR: Garvey, Redmond (correspondence)
CORPORATE SOURCE: Current Drugs Ltd., Middlesex House, 34-42 Cleveland Street, London W1T 4LB, United Kingdom. redmond.garvey@current-drugs.com
SOURCE: IDrugs, (2002) Vol. 5, No. 7, pp. 640-644. ISSN: 1369-7056 CODEN: IDRUFN
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Conference Article; (Conference paper)
FILE SEGMENT: 016 Cancer
029 Clinical and Experimental Biochemistry
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
LANGUAGE: English
ENTRY DATE: Entered STN: 23 Oct 2003
Last Updated on STN: 23 Oct 2003

L18 ANSWER 7 OF 9 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2000429823 EMBASE
TITLE: Tirapazamine: A bioreductive anticancer drug that exploits tumour hypoxia.

AUTHOR: Denny, W.A. (correspondence); Wilson, W.R.
CORPORATE SOURCE: Auckland Cancer Society Res. Centre, Faculty of Medicine/Health Science, The University of Auckland, Private Bag 92019, Auckland 1000, New Zealand. b.denny@auckland.ac.nz
SOURCE: Expert Opinion on Investigational Drugs, (2000) Vol. 9, No. 12, pp. 2889-2901.
Refs: 112
ISSN: 1354-3784 CODEN: EOIDER
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 016 Cancer
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 29 Dec 2000
Last Updated on STN: 29 Dec 2000

AB Tirapazamine is the second clinical anticancer drug (after porfiromycin) that functions primarily as a hypoxia-selective cytotoxin. Hypoxic cells in tumours are relatively resistant to radiotherapy and to some forms of chemotherapy and are also biologically aggressive, thus representing an important target population in oncology. Tirapazamine undergoes metabolism by reductases to form a transient oxidising radical that can be efficiently scavenged by molecular oxygen in normal tissues to re-form the parent compound. In the absence of oxygen, the oxidising radical abstracts a proton from DNA to form DNA radicals, largely at C4' on the ribose ring. Tirapazamine can also oxidise such DNA radicals to cytotoxic DNA strand breaks. It therefore shows substantial selective cytotoxicity for anoxic cells in culture (typically 100-fold more potent than under oxic conditions) and for the hypoxic subfraction of cells in tumours. Preclinical studies showed enhanced activity of combinations of tirapazamine with radiation (to kill oxygenated cells) and with conventional cytotoxics, especially cisplatin (probably through inhibition of repair of cisplatin DNA cross-links in hypoxic cells). Phase II and III clinical studies of tirapazamine and cisplatin in malignant melanoma and non-small cell lung cancer suggest that the combination is more active than cisplatin alone and preliminary results with advanced squamous cell carcinomas of the head and neck indicate that tirapazamine may enhance the activity of cisplatin with fractionated radiotherapy.

L18 ANSWER 8 OF 9 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
ACCESSION NUMBER: 2001:191481 BIOSIS
DOCUMENT NUMBER: PREV200100191481
TITLE: Pharmacological aspects of targeting cancer gene therapy to endothelial cells.
AUTHOR(S): Sedlacek, H. H. [Reprint author]
CORPORATE SOURCE: Central Biotechnology, Aventis Pharma Deutschland GmbH, 35001, Marburg, Germany
hans-harald.sedlacek@aventis.com
SOURCE: Critical Reviews in Oncology-Hematology, (March, 2001) Vol. 37, No. 3, pp. 169-215. print.
ISSN: 1040-8428.
DOCUMENT TYPE: Article
General Review; (Literature Review)
LANGUAGE: English
ENTRY DATE: Entered STN: 20 Apr 2001
Last Updated on STN: 18 Feb 2002

L18 ANSWER 9 OF 9 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN

```
ACCESSION NUMBER:    1990:348301  BIOSIS
DOCUMENT NUMBER:     PREV199039043562; BR39:43562
TITLE:               SYNTHESIS AND PROPERTIES OF A NEW ANALOG OF FLAVONE ACETIC
                     ACID 5 6 DIMETHYLXANTHENONE-
                     4-ACETIC ACID.
AUTHOR(S):           BAGULEY B C [Reprint author]; DENNY W A; ATWELL G J;
                     REWCASTLE G W; CHING L-M; THOMSEN L L; ZHUANG L
CORPORATE SOURCE:    CANCER RES LAB, UNIV AUCKLAND SCH MED, AUCKLAND, NEW
                     ZEALAND
SOURCE:              Proceedings of the American Association for Cancer Research
                     Annual Meeting, (1990) Vol. 31, pp. 413.
                     Meeting Info.: 81ST ANNUAL MEETING OF THE AMERICAN
                     ASSOCIATION FOR CANCER RESEARCH, WASHINGTON, D.C., USA, MAY
                     23-26, 1990. PROC AM ASSOC CANCER RES ANNU MEET.
                     ISSN: 0197-016X.
DOCUMENT TYPE:       Conference; (Meeting)
FILE SEGMENT:        BR
LANGUAGE:            ENGLISH
ENTRY DATE:          Entered STN: 26 Jul 1990
                     Last Updated on STN: 27 Jul 1990


=> d his

     (FILE 'HOME' ENTERED AT 13:24:45 ON 30 SEP 2010)

     FILE 'REGISTRY' ENTERED AT 13:24:56 ON 30 SEP 2010
L1             3 S DMXAA

     FILE 'CAPLUS' ENTERED AT 13:25:13 ON 30 SEP 2010
L2           216 S L1

     FILE 'REGISTRY' ENTERED AT 13:25:20 ON 30 SEP 2010
L3            15 S GEMCITABINE

     FILE 'CAPLUS' ENTERED AT 13:25:29 ON 30 SEP 2010
L4          6347 S L3
L5             9 S L2 AND L4
L6             9 DUP REM L5 (0 DUPLICATES REMOVED)
L7           196 S L2 AND (CANCER OR TUMOR OR NEOPLASM)
L8            10 S L7 AND AD<20020903
L9            10 DUP REM L8 (0 DUPLICATES REMOVED)

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 13:26:51 ON 30 SEP 2010

     FILE 'CAPLUS' ENTERED AT 13:26:57 ON 30 SEP 2010
                SET SMARTSELECT ON
L10           SEL L2 1- TI :     777 TERMS
                SET SMARTSELECT OFF

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 13:27:06 ON 30 SEP 2010

     FILE 'REGISTRY' ENTERED AT 13:27:27 ON 30 SEP 2010
                SET SMARTSELECT ON
L11           SEL L1 1- CHEM :      12 TERMS
                SET SMARTSELECT OFF

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 13:27:28 ON 30 SEP 2010
L12          741 S L11
L13          741 S L1 OR L12
L14          676 S L13 AND (CANCER OR TUMOR OR TUMOUR OR NEOPLASM)
L15          240 S L14 AND PD<20020903
```

```
L16          115 DUP REM L15 (125 DUPLICATES REMOVED)
L17            0 S L16 AND GEMCITABINE
L18            9 S L16 AND (LUNG OR PANCREA?)

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    24.28     150.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -16.15

STN INTERNATIONAL LOGOFF AT 13:30:25 ON 30 SEP 2010
```